{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:02:20Z","timestamp":1791820940888,"version":"4.3.4"},"reference-count":326,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET\/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.<\/jats:p>","DOI":"10.6004\/jnccn.2020.0026","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T19:31:47Z","timestamp":1591385507000},"page":"755-781","source":"Crossref","is-referenced-by-count":124,"title":["Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"18","author":[{"given":"Richard T.","family":"Hoppe","sequence":"first","affiliation":[{"name":"1Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"1Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[{"name":"2UCSF Helen Diller Family Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"3The Sidney Kimmel Comprehensive Cancer Center at John Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"4Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste M.","family":"Bello","sequence":"additional","affiliation":[{"name":"5Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil M.","family":"Benitez","sequence":"additional","affiliation":[{"name":"1Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Bierman","sequence":"additional","affiliation":[{"name":"6Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Boughan","sequence":"additional","affiliation":[{"name":"7Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[{"name":"8The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"9Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"10Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"11City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"12Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[{"name":"13Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"14Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"15University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[{"name":"16University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"17Fox Chase Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"18Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"19The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"McConathy","sequence":"additional","affiliation":[{"name":"20O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McKinney","sequence":"additional","affiliation":[{"name":"21Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Metzger","sequence":"additional","affiliation":[{"name":"22St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morgan","sequence":"additional","affiliation":[{"name":"23Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Mulroney","sequence":"additional","affiliation":[{"name":"24UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rabinovitch","sequence":"additional","affiliation":[{"name":"25University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Rosenspire","sequence":"additional","affiliation":[{"name":"26Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Seropian","sequence":"additional","affiliation":[{"name":"27Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Tao","sequence":"additional","affiliation":[{"name":"28Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"9Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[{"name":"29Memorial Sloan Kettering Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Burns","sequence":"additional","affiliation":[{"name":"30National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndiya","family":"Ogba","sequence":"additional","affiliation":[{"name":"30National Comprehensive Cancer Network."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref981","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"key":"ref2411","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"ref3041","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"Gopal","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref2261","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.15585","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde","year":"2018","journal-title":"Br J Haematol"},{"key":"ref2281","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/cncr.21253","article-title":"A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma","volume":"104","author":"Isasi","year":"2005","journal-title":"Cancer"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: Long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1083-8791(03)00205-2","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3121","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"ref2651","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref2911","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"ref3271","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref2591","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2070","article-title":"XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes","volume":"31","author":"Jagadeesh","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref2341","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin\u2019s disease: long-term results of a randomized trial of radiotherapy alone","volume":"19","author":"D\u00fchmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref411","first-page":"CD012643","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"9","author":"Aldin","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2241","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref2271","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref2981","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.2001.02714.x","article-title":"Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease","volume":"113","author":"Mart\u00edn","year":"2001","journal-title":"Br J Haematol"},{"key":"ref1181","first-page":"98","article-title":"High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes","volume":"3","author":"Wheeler","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1151","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref2221","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.prro.2012.12.006","article-title":"Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy","volume":"3","author":"Filippi","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/annonc\/mdp487","article-title":"Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin\u2019s lymphoma followed by autologous stem-cell transplantation","volume":"21","author":"Fern\u00e1ndez de Larrea","year":"2010","journal-title":"Ann Oncol"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref2391","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref171","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/10428190801888704","article-title":"Early interim PET scan in Hodgkin lymphoma: where do we stand?","volume":"49","author":"Gallamini","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref3181","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2351","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/02841860310013346","article-title":"A systematic overview of radiation therapy effects in Hodgkin\u2019s lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol"},{"key":"ref2491","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref3311","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref3301","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/annonc\/mdp487","article-title":"Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin\u2019s lymphoma followed by autologous stem-cell transplantation","volume":"21","author":"Fern\u00e1ndez de Larrea","year":"2010","journal-title":"Ann Oncol"},{"key":"ref3161","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.V126.23.582.582","article-title":"Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)","volume":"126","author":"Garcia-Sanz","year":"2015","journal-title":"Blood"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin\u2019s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref2811","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3324\/haematol.2011.056010","article-title":"Positron emission tomography\/computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs","volume":"97","author":"El-Galaly","year":"2012","journal-title":"Haematologica"},{"key":"ref3261","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score \u22653, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"key":"ref2531","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score \u22653, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref2751","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref921","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1008357126404","article-title":"18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin\u2019s lymphoma","volume":"12","author":"de Wit","year":"2001","journal-title":"Ann Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"ref2061","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.14694\/EDBK_159036","article-title":"Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT","volume":"35","author":"Lynch","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2007.2001","article-title":"NCCN task force report: positron emission tomography (PET)\/computed tomography (CT) scanning in cancer","volume":"5","author":"Podoloff","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2361","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.939","article-title":"Fertility preservation after chemotherapy for Hodgkin lymphoma","volume":"28","author":"van der Kaaij","year":"2010","journal-title":"Hematol Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref3071","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mds542","article-title":"Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial","volume":"24","author":"Advani","year":"2013","journal-title":"Ann Oncol"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin\u2019s disease: long-term results of a randomized trial of radiotherapy alone","volume":"19","author":"D\u00fchmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref2871","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"ref1711","article-title":"College of Radiology ACR SPR Practice Parameters for Performing FDG PET in Accessed Available at https www acr org - media ACR Files Practice Parameters FDG PET CT pdf la en","volume":"24","author":"January","year":"2016","journal-title":"American Oncology"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br J Haematol"},{"key":"ref2601","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/07357900701788098","article-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"26","author":"Abali","year":"2008","journal-title":"Cancer Invest"},{"key":"ref2631","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.939","article-title":"Fertility preservation after chemotherapy for Hodgkin lymphoma","volume":"28","author":"van der Kaaij","year":"2010","journal-title":"Hematol Oncol"},{"key":"ref2181","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2011.12.034","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.14694\/EDBK_159036","article-title":"Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT","volume":"35","author":"Lynch","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin\u2019s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref2441","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref3031","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref3201","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: Long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"key":"ref2521","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref2741","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group","volume":"92","author":"Kriz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref2571","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref2461","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B","article-title":"Prognostic significance of the number of involved areas in the early stages of Hodgkin\u2019s disease","volume":"54","author":"Tubiana","year":"1984","journal-title":"Cancer"},{"key":"ref2451","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref2401","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref3151","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R","article-title":"The significance of mediastinal involvement in early stage Hodgkin\u2019s disease","volume":"42","author":"Mauch","year":"1978","journal-title":"Cancer"},{"key":"ref2501","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group","volume":"92","author":"Kriz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref3221","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","article-title":"Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010","volume":"51","author":"Meignan","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref2101","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref2541","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2961","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"key":"ref2781","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/10428190801888704","article-title":"Early interim PET scan in Hodgkin lymphoma: where do we stand?","volume":"49","author":"Gallamini","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref2381","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2014.57.8138","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial","volume":"33","author":"Advani","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"ref2821","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br J Haematol"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/JCO.2018.36.15_suppl.7542","article-title":"Long-term follow-up of brentuximab vedotin \u00b1 dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"key":"ref3081","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-03-703470","article-title":"Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.29277","article-title":"Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy","volume":"121","author":"Gandikota","year":"2015","journal-title":"Cancer"},{"key":"ref1691","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref2611","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref3241","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref3141","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref11","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.prro.2012.12.006","article-title":"Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy","volume":"3","author":"Filippi","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref1851","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"ref2511","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref2731","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor \u2020","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref3341","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"ref3001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a059252","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez","year":"1995","journal-title":"Ann Oncol"},{"key":"ref2291","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2007.2001","article-title":"NCCN task force report: positron emission tomography (PET)\/computed tomography (CT) scanning in cancer","volume":"5","author":"Podoloff","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3211","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"ref3011","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"ref2301","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","article-title":"State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83)","volume":"15","author":"Gr\u00e9goire","year":"2011","journal-title":"Cancer Radiother"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2018-05-852129","article-title":"Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1748-717X-2-20","article-title":"Influence of different treatment techniques on radiation dose to the LAD coronary artery","volume":"2","author":"Nieder","year":"2007","journal-title":"Radiat Oncol"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin\u2019s lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1008357126404","article-title":"18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin\u2019s lymphoma","volume":"12","author":"de Wit","year":"2001","journal-title":"Ann Oncol"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref2851","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1083-8791(03)00205-2","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O\u2019Connor","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2801","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","article-title":"Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle","volume":"20","author":"Brice","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann Oncol"},{"key":"ref2891","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","article-title":"Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"ref2211","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"ref2641","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref3331","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref2971","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma","volume":"93","author":"Labrador","year":"2014","journal-title":"Ann Hematol"},{"key":"ref3021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin\u2019s lymphoma: a reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1182\/blood.V118.21.3643.3643","article-title":"Incidence and predictors of bleomycin pulmonary toxicity in Hodgkin lymphoma (HL) patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)","volume":"118","author":"Sun","year":"2011","journal-title":"Blood"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mdl496","article-title":"Phase I\/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin\u2019s lymphoma","volume":"18","author":"Evens","year":"2007","journal-title":"Ann Oncol"},{"key":"ref1981","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin\u2019s lymphoma: the importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"ref2231","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"ref2551","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00689103","article-title":"VIM-D salvage chemotherapy in Hodgkin\u2019s disease","volume":"27","author":"Phillips","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood.V124.21.501.501","article-title":"Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed\/refractory HL prior to AHCT","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref2371","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"ref2771","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"ref3111","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin\u2019s lymphoma: the importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.2147\/OTT.S70264","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez","year":"2014","journal-title":"OncoTargets Ther"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiol.2441060810","article-title":"Hodgkin disease: diagnostic value of FDG PET\/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?","volume":"244","author":"Schaefer","year":"2007","journal-title":"Radiology"},{"key":"ref2581","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin\u2019s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref2901","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref3061","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref3231","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref2681","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1182\/blood.V118.21.3643.3643","article-title":"Incidence and predictors of bleomycin pulmonary toxicity in Hodgkin lymphoma (HL) patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)","volume":"118","author":"Sun","year":"2011","journal-title":"Blood"},{"key":"ref2761","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref3291","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mdl496","article-title":"Phase I\/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin\u2019s lymphoma","volume":"18","author":"Evens","year":"2007","journal-title":"Ann Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B","article-title":"Prognostic significance of the number of involved areas in the early stages of Hodgkin\u2019s disease","volume":"54","author":"Tubiana","year":"1984","journal-title":"Cancer"},{"key":"ref2991","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00689103","article-title":"VIM-D salvage chemotherapy in Hodgkin\u2019s disease","volume":"27","author":"Phillips","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiol.2441060810","article-title":"Hodgkin disease: diagnostic value of FDG PET\/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?","volume":"244","author":"Schaefer","year":"2007","journal-title":"Radiology"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"ref3101","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.15585","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.1995.13.2.396","article-title":"Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation","volume":"13","author":"Colwill","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref2841","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"ref2791","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/cncr.21253","article-title":"A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma","volume":"104","author":"Isasi","year":"2005","journal-title":"Cancer"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2070","article-title":"XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes","volume":"31","author":"Jagadeesh","year":"2013","journal-title":"Hematol Oncol"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"ref2931","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/07357900701788098","article-title":"Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma","volume":"26","author":"Abali","year":"2008","journal-title":"Cancer Invest"},{"key":"ref2661","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"key":"ref1971","first-page":"1225","article-title":"Prognostic value of PET using 18F-FDG in Hodgkin\u2019s disease for posttreatment evaluation","volume":"44","author":"Guay","year":"2003","journal-title":"J Nucl Med"},{"key":"ref2091","first-page":"CD012643","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"9","author":"Aldin","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2621","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2431","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00277-014-2114-0","article-title":"ESHAP as salvage therapy for relapsed or refractory Hodgkin\u2019s lymphoma","volume":"93","author":"Labrador","year":"2014","journal-title":"Ann Hematol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/02841860310013346","article-title":"A systematic overview of radiation therapy effects in Hodgkin\u2019s lymphoma","volume":"42","author":"Gustavsson","year":"2003","journal-title":"Acta Oncol"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref2321","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mds542","article-title":"Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial","volume":"24","author":"Advani","year":"2013","journal-title":"Ann Oncol"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2010.491137","article-title":"Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium","volume":"51","author":"Gopal","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref2001","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R","article-title":"The significance of mediastinal involvement in early stage Hodgkin\u2019s disease","volume":"42","author":"Mauch","year":"1978","journal-title":"Cancer"},{"key":"ref2421","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"ref2711","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref2331","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref3171","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2141.2001.02714.x","article-title":"Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease","volume":"113","author":"Mart\u00edn","year":"2001","journal-title":"Br J Haematol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","article-title":"FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas","volume":"44","author":"Barrington","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref2691","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref2701","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin\u2019s lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2014.57.8138","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial","volume":"33","author":"Advani","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref3351","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood.V124.21.501.501","article-title":"Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed\/refractory HL prior to AHCT","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref3281","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref2561","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3324\/haematol.2011.056010","article-title":"Positron emission tomography\/computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs","volume":"97","author":"El-Galaly","year":"2012","journal-title":"Haematologica"},{"key":"ref3051","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.2147\/OTT.S70264","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez","year":"2014","journal-title":"OncoTargets Ther"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref3131","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"(18)F-FDG PET\/CT bone\/bone marrow findings in Hodgkin\u2019s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref2721","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/JCO.2018.36.15_suppl.7542","article-title":"Long-term follow-up of brentuximab vedotin \u00b1 dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref2951","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.1995.13.2.396","article-title":"Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation","volume":"13","author":"Colwill","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref3251","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.29277","article-title":"Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy","volume":"121","author":"Gandikota","year":"2015","journal-title":"Cancer"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.V126.23.582.582","article-title":"Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)","volume":"126","author":"Garcia-Sanz","year":"2015","journal-title":"Blood"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","article-title":"State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83)","volume":"15","author":"Gr\u00e9goire","year":"2011","journal-title":"Cancer Radiother"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref3191","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref2861","first-page":"98","article-title":"High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin\u2019s disease: a prognostic model for treatment outcomes","volume":"3","author":"Wheeler","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref2831","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref2201","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1748-717X-2-20","article-title":"Influence of different treatment techniques on radiation dose to the LAD coronary artery","volume":"2","author":"Nieder","year":"2007","journal-title":"Radiat Oncol"},{"key":"ref2881","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.22714","article-title":"Pretransplant positive positron emission tomography\/gallium scans predict poor outcome in patients with recurrent\/refractory Hodgkin lymphoma","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"key":"ref291","first-page":"1225","article-title":"Prognostic value of PET using 18F-FDG in Hodgkin\u2019s disease for posttreatment evaluation","volume":"44","author":"Guay","year":"2003","journal-title":"J Nucl Med"},{"key":"ref3091","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","article-title":"Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study","volume":"34","author":"Santoro","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a059252","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez","year":"1995","journal-title":"Ann Oncol"},{"key":"ref31","article-title":"College of Radiology ACR SPR Practice Parameters for Performing FDG PET in Accessed Available at https www acr org - media ACR Files Practice Parameters FDG PET CT pdf la en","volume":"24","author":"January","year":"2016","journal-title":"American Oncology"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"key":"ref2251","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijrobp.2010.05.007","article-title":"Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref2941","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","article-title":"ESHAP is an active regimen for relapsing Hodgkin\u2019s disease","volume":"10","author":"Aparicio","year":"1999","journal-title":"Ann Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin\u2019s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","article-title":"ESHAP is an active regimen for relapsing Hodgkin\u2019s disease","volume":"10","author":"Aparicio","year":"1999","journal-title":"Ann Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"(18)F-FDG PET\/CT bone\/bone marrow findings in Hodgkin\u2019s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood-2012-03-403790","article-title":"Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?","volume":"120","author":"Gallamini","year":"2012","journal-title":"Blood"},{"key":"ref2311","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin\u2019s lymphoma: a reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin\u2019s lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2671","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/10428194.2018.1515939","article-title":"The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor \u2020","volume":"60","author":"Andersen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p755.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/6\/article-p755.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:22:02Z","timestamp":1722993722000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/6\/article-p755.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":326,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.0026","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}